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In spite of current recommended safe handling procedures, the potential for the exposure of healthcare providers
to hazardous drugs exists in the workplace. A reliance on biological safety cabinets to provide total protection
against the exposure to hazardous drugs is insufficient. Preventing workplace contamination is the best strategy to
minimize cytotoxic drug exposure in healthcare providers. This study was conducted to compare surface
contamination and personnel exposure to cyclophosphamide before and after the implementation of a closed-
system drug transfer device, PhaSeal, under the influence of cleaning according to the Japanese guidelines.
Personnel exposure was evaluated by collecting 24 h urine samples from 4 pharmacists. Surface contamination was
assessed by the wiping test. Four of 6 wipe samples collected before PhaSeal indicated a detectable level of
cyclophosphamide. About 7 months after the initiation of PhaSeal, only one of 6 wipe samples indicated a
detectable level of cyclophosphamide. Although all 4 employees who provided urine samples had positive results
for the urinary excretion of cyclophosphamide before PhaSeal, these levels returned to minimal levels in 2
pharmacists after PhaSeal. In combination with the biological safety cabinet and cleaning according to the
Japanese guidelines, PhaSeal further reduces surface contamination and healthcare providers exposure to
cyclophosphamide to almost undetectable levels.
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guidelinesBackground
Many drugs used in the treatment of cancer are consid-
ered to be hazardous to healthcare workers. Over the last
20 years, several studies have reported environmental con-
tamination with hazardous drugs in hospital pharmacies
(Castiglia et al. 2008; Ensslin et al. 1994; Hedmer et al.
2008; McDevitt et al. 1993; Sessink et al. 1992; Sessink
et al. 1995; Sugiura et al. 2011; Vandenbroucke and Robays
2001; Yoshida et al. 2011). In addition, hazardous drugs
were inadvertently absorbed, as determined by the pres-
ence of parent compounds and/or their metabolites in
the urine of health care workers (Ensslin et al. 1997;
Schreiber et al. 2003; Sessink et al. 1992; Sessink et al.* Correspondence: okudam@clin.medic.mie-u.ac.jp
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in any medium, provided the original work is p1994; Sessink et al. 1997). Due to the potential health
risks of hazardous drugs, the increasing use of these
drugs, and continuing environmental contamination, the
National Institute for Occupational Safety and Health
(NIOSH) published an alert for antineoplastic and other
hazardous drugs used in healthcare settings (National
Institute for Occupational Safety and Health NIOSH
2004). Based upon recommendations, the American
Society of Health-System Pharmacists (ASHP) and the
International Society of Oncology Pharmacy Practi-
tioners (ISOPP) have published updated guidelines on
the safe-handling of cytotoxic and hazardous drugs
(American Society of Health-System Pharmacists guide-
lines on handling hazardous drugs 2006; International
Society of Oncology Pharmacy Practitioners Standards
Committee. ISOPP standards of practice 2007).
In Japan, guidelines for handling antineoplastic drugs
in hospitals were issued by the Japan Pharmaceuticalan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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more, these guidelines were revised and published as
“Compounding Manuals for Antineoplastic Agents” in
2005 and 2009 (Kitada et al.). The Japanese Society of
Hospital Pharmacists (JSHP) academic committee then
updated and published the “Guidelines for Compounding
Antineoplastic Agents,” referring to the “ALERT” in
“Preventing Occupational Exposure to Antineoplastic and
Other Hazardous Drugs in Health Care Settings” an-
nounced by the NIOSH and guidelines from the ASHP.
Introduction of the biological safety cabinet (BSC) for
the preparation of anticancer drugs is limited, with only
35.2% of hospitals using the BSC in Japan, even though
guidelines on the preparation of anticancer drugs exist
(JSHP. 2012). Recently, the advantage of closed-system
drug transfer device (CSTD) is recognized to prevent or
reduce exposure of healthcare providers from hazardous
drugs. The CSTD is a device that mechanically prevents
contamination of the environmental substances into a
drug solution and the escape of hazardous drug or vapor
concentrations outside the system. In addition, only
10.7% of hospitals in Japan currently use the CSTD
(JSHP. 2012), although pharmacists in 90% or more of
hospitals recognize the usefulness of the CSTD. Reim-
bursement of technical fees for the use of CSTD to the
medical institutions under the medical insurance system
were introduced in 2010, and the value was raised in
2012 for the preparation of volatile anticancer drugs,
i.e. cyclophosphamide, ifosfamide and bendamustine;
therefore, the use of the CSTD in a hospital setting has
been increasing in Japanese hospitals. Interestingly, there
is no authorized pharmacy technician system in Japan,
and, as such, pharmacists are regarded as being primar-
ily in charge of compounding hazardous drugs.
At Yamada Red Cross Hospital (current name: Ise Red
Cross Hospital), we developed institutional manuals for
compounding anticancer drugs in reference to the above
guidelines and began to use BSC Class IIB2 and personal
protective equipment (PPE) in the compounding room of
the pharmacy department. Each pharmacist in charge of
compounding anticancer drugs wear two layers of gloves,
a disposable polypropylene gown with long sleeves and
closed fronts, a disposable cap and a disposable surgical
mask. In addition, the BSC and floor of the compounding
room are wiped after compounding according to the
Japanese guidelines. However, we revealed that cyclophos-
phamide (CP) was still detected at the sites of the wipe
tests as well as in urine samples from all pharmacists in
charge of CP compounding (Tanimura et al. 2009). Sev-
eral studies have shown nearly complete containment
or reduction in surface contamination accompanying
preparation and/or administration of hazardous drug
(Connor et al. 2002; Vandenbroucke and Robays 2001;
Wick et al. 2003).We conducted this study to evaluate the effects of the
CSTD on surface contamination and exposure of phar-
macists in charge of compounding CP in a Japanese hos-
pital setting.Materials and methods
Yamada Red Cross Hospital is a community hospital in
Mie prefecture Japan with 655 beds for inpatients desig-
nated for the treatment of cancer. In the hospital, 7061
patients were treated with anticancer agents in the year
2010. The study design was approved by the Institutional
Review Board at Yamada Red Cross Hospital and all sub-
jects provided written.Wipe tests
A total of 6 sites in the anticancer drugs compounding
room of the pharmacy were subjected to wipe tests for
CP (Shionogi & Co., Ltd., Osaka, Japan) contamination
on September 7, 2007 (first test) using Cyto Wipe Kits
(Exposure Control B.V., Al Wijchen, Netherlands). On
April 2008, we began to use the CSTD (PhaSealW; Car-
mel Pharma ab, Goteborg, Sweden), and then the same
tests were conducted on March 4, 2009 (second test)
eleven months after the implementation of PhaSeal. The
same pharmacist collected the wipe samples, and this
study was faithfully done according to the wipe manual.
The test sites were: 1. work surface of the BSC; 2. airfoil
inside the BSC; 3. the floor in front of the BSC; 4. the
central work table; 5. the work table with a telephone
and personal computer in the office area; and 6. the
floor of the entrance into the compounding room
(Figure 1). We wiped exactly the same position of surface
before and after implementation of PhaSeal by assuring
the distance from the edge of the wall and the table. All
wipe samples were taken at the end of the routine prep-
aration of hazardous drugs before daily cleaning. We
used 0.03M sodium hydroxide, 2% sodium hypochlorite,
and 1% sodium thiosulfate to wipe clean the surface of
BSC. The floors of the room were cleaned using dispos-
able sheets, which were dampened with ethanol and de-
tergent. The tables were wiped using a disposable
nonwoven rayon fabric dampened with ethanol. The
floors and tables of the room were wiped every day.
Cyto Wipe Kits were used for all sampling. These kits
contained standardized supplies for taking samples, in-
cluding certified drug-free sampling tissues, dropper bot-
tles containing sampling solution, storage containers,
latex gloves, and labels. Each predetermined sampling
location was marked with colored tape and measured to
determine the sample area. All sample containers were
pre-labeled with the collection date and a coded number
that identified the study site and sample location.
Figure 1 Sites of the wipe test in the chemotherapy preparation room at the pharmacy.
Miyake et al. SpringerPlus 2013, 2:273 Page 3 of 7
http://www.springerplus.com/content/2/1/273Urine test
Four pharmacists (3 males and 1 female) who compounded
CP collected their own urine samples over 24 h. It would
be collected for 24 h during the period of August 30
through September 11, 2007 based on the schedule of the
pharmacist. These pharmacists collected urine samples at
every urination from prior to compounding anticancer
drugs to the next morning. More than 7 months after the
initiation of PhaSeal, urine samples were collected again
from the same 4 pharmacists between November 7, 2008
and March 17, 2009.
As stipulated in the instruction manual, we collected
samples using Cyto Urine Kits (Exposure Control B.V.,
Al Wijchen, Netherlands). Using measuring cups, we
took urine samples from the test pharmacists. The sam-
pling times and volume of urine were recorded. We
placed 5 mL of the urine collected into a plastic con-
tainer with a screw-on lid. The containers were stored in
a freezer at −80 degrees C. The amount of CP prepared
by these pharmacists on the day of the urine test was
also recorded. All 4 pharmacists did not take any medi-
cines that may have influenced CP metabolism.Analysis of samples
Frozen wipe and urine samples were transported with
dry ice to Exposure Control for determination of CP
level. Samples were analyzed with a Varian Saturn 4D
GC-MS/MS ion-trap system with a Varian 8200 auto
sampler, controlled by a computer. The detection limits
of intact CP were 0.10 ng/mL for the wipe test and
0.01 ng/mL for the urine test.Results
Wipe tests
The results of the wipe tests were shown in Table 1. The
contamination per cm2 was calculated. Before PhaSeal,
CP was detected at 4 test sites in the compounding
room in the pharmacy: 1. the work surface; 2. airfoil in-
side the BSC; 3. the floor in front of the BSC; 6. the floor
of the entrance to the compounding room. After the in-
stallation of PhaSeal, CP was not detected in any other
locations except for the floor of the entrance to the
compounding room.
Urine test
The mean amount of CP compounded by pharmacists
on the day of the urine test after the installation of
PhaSeal was 11.9% (3945 mg) higher than that before
the installation of PhaSeal (3525 mg). Before PhaSeal, 34
urine samples were collected from four pharmacists, and
CP was detected in 26 samples. The total amount of CP
excreted in each pharmacist was 34.9, 27.0, 56.5, and
71.3 ng/24 h (Table 2), respectively, with mean value
47.4 ng/24 h. After PhaSeal, 31 urine samples were col-
lected from the same four pharmacists, and CP was
detected in two urine samples only from two pharma-
cists. The total amount of CP in these samples was 6.4
and 7.8 ng/24 h, respectively, with mean value 3.6 ng/
24 h (Table 2).
Discussion
Several steps in the compounding anticancer drugs cre-
ate conditions that may allow the escape of the drug into
the compounding room as well as the work surface of
Table 1 Concentration of CP in wipe samples (ng/cm2) in the preparation on room
First test Second test





1 Work place 3900 0.28 45 0.012 nd - -
2 Air foil 1463 0.54 86 0.059 nd - -
3 Floor in front 4900 0.17 27 0.006 nd - -
4 Table 2442 nd - - nd - -
5 Office area 3060 nd - - nd - -
6 Floor 4900 0.15 24 0.005 0.24 38 0.008
nd not detected. The first test was conducted on September 7, 2007. The second test was conducted on March 4, 2009. The contamination per cm2 was
calculated assuming 100% recovery and wipe efficiency. The detection limit for cyclophosphamide was 0.10 ng/mL NaOH. PhaSealW was not used for the first test,
and was used for the second.
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tion of an aerosol due to over or under pressure inside
the drug vial. An aerosol forms when the vial membrane
is punctured and the air pressure within the vial quickly
equalizes with ambient air pressure. The aerosol settles
on work surfaces and other exposed areas in the imme-
diate environment. Working with hazardous drugs in
health care settings has demonstrated measurable urine
concentrations accompanied within fertility, miscarriage,
and birth defects (Selevan et al. 1985; Valanis et al. 1997;
Valanis et al. 1999). Cautionary reports described that
lymphocyte DNA damage and chromosome 5 and 7 ab-
normalities may be induced in healthcare providers
handling hazardous drugs (McDiarmid et al. 2010; Sasaki
et al. 2008; Yoshida et al. 2006). Although the BSC may
reduce environmental contamination by an aerosol andTable 2 Total amount of CP in urine samples (ng/24 h) from f
Pharmacist Amount of CP prepared (mg/day) Number of samples













The first test was conducted between August 30 and September 11, 2007.
The second test was conducted between November 7, 2008 and March 17, 2009.
The amount of CP prepared was measured on the day of the urine test.
PhaSealW was not used for the first test, and was used for the second test.spills of hazardous drugs, it cannot completely prevent
environmental contamination.
The Japanese guideline “Guideline for aseptic handling
of injection and antineoplastic drugs” was developed
referring to the guidelines of the ASHP and ISOPP
(Nabeshima et al. 2008). In addition to the use of the
CSTD, cleaning of the BSC is also recommended. We
reported that CP was detected in 4 wipe samples with
the mean CP concentration being 0.014 ng/cm2 before
PhaSeal was used; however, CP was detected in only 1
wipe sample at 0.001 ng/cm2 after PhaSeal was installed.
The mean amount of CP in urine samples was also re-
duced to 7.1% with PhaSeal relative to that before
PhaSeal. There are three features in our study. 1; The
training of pharmacists to use PhaSeal. In the present
study, the effect of PhaSeal was evaluated more than 7our pharmacists
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portance of training for using the CSTD has also been
described in the guidelines of the ISOPP (International
Society of Oncology Pharmacy Practitioners Stan-
dards Committee. ISOPP standards of practice 2007).
2; Method of cleaning the environment. There is an in-
creased risk of inhaling CP when the inside of the BSC
being cleaned with ethanol (Pethran et al. 2003). We
prevented the inhalation of hazardous drugs by cleaning
the compounding room according to the Japanese guide-
line (Nabeshima et al. 2008). The inside of the BSC was
wiped down 4 times with gauze, which were consecu-
tively moistened with 0.03 M NaOH, 2% sodium hypo-
chlorite, 1% sodium thiosulfate, and 80% ethanol
(Mochizuki et al. 2008). The floor was also cleaned using
disposable sheets every day. 3; Analysis of samples. Our
samples were measured by Exposure Control. A few
wipe samples were collected in this study, because of
the small number of pharmacists and limited budget
for the cost of analytical methods. Therefore, our re-
sults were shown by the mean value. However our re-
sult indicates that exposure to CP is decreased by
using PhaSeal and cleaning the BSC and floor
according to the guidelines.
In the US, four quantitative studies have been
conducted to evaluate the use of PhaSeal in reducing
contamination of the workplace with hazardous drugs
(Connor et al. 2002; Harrison et al. 2006; Nyman et al.
2007; Wick et al. 2003). Sessink et al. tested PhaSeal in
22 US hospitals and concluded that a marked reduction
in environmental contamination could be achieved if
the compounding was performed using PhaSeal
(Sessink et al. 2011). In Japan, Yoshida reported that
CP was detected in all wipe samples, and also indi-
cated that the mean amount of CP in urine samples
after the installation of PhaSeal (Yoshida et al. 2009).
These reports are comparable with our current study
that reduction of healthcare provider exposure to
hazardous drugs was achieved by standard handling
of the drug with the CSTD in accordance with
Japanese guidelines.Table 3 The risk of developing additional cancer due to occu
First test (before PhaSealW)
Pharmacist CP (ng/24 h) Cancer risk*
1 34.9 0.27 -1.94
2 27.0 0.21 -1.50
3 56.5 0.44 - 3.14
4 71.3 0.55 -3.96
nd: not detected.
The first test was conducted on September 12, 2007.
The second test was conducted on March 18, 2009.
*Cancer risk: extra cancer cases in a million workers each year.Our results show that a reduction in environmental
contamination can be achieved if the preparation is
performed by using PhaSeal. However, even with the use
of the PhaSeal, environmental contamination was still
observed. Possible sources contributing to this observa-
tion may include remaining contamination from the past
and introduction of new contamination via external con-
tamination on the drug vials. Hedmer et al. (2005) and
Connor et al. (2005) had been published showing surface
contamination of antineoplastic drug vials. While our
current study show reduction in contamination, it was
difficult to evaluate exactly whether PhaSeal completely
prevent the exposure of healthcare professionals to CP
because significant amount of CP may be carried in from
the package surface of CP during compounding.
Up to 25% of CP administered is excreted in the urine
as an unchanged form for 24 h, and more than 50% of CP
is metabolized to 4-ketocyclophosphamide and carboxy-
phosphamide via 4-hydroxycyclophosphamide by cyto-
chrome P450 and oxidase in the liver (Fujita Fujita 1986).
Tanimura et al. (2009) reported that 0.24 ng/mL CP was
detected at 26 h after compounding CP. It is obvious that
detectable levels of CP and its metabolites are still present
in the urine of the pharmacists. Since exposure to CP over
a long period of time may increase the risk of the accumu-
lation of its metabolites in the body, further studies are
needed to clarify the exposure evaluation including the
urinary metabolized CP level. Sessink described the risk of
developing additional cancer due to systematic exposure
to CP in his report (Sessink et al. 1995). By extra polating
animal studies to patient data, the calculated chance of de-
veloping additional cancer was between 1.4 and 10 add-
itional cancer cases per year per million workers when
exposed daily to CP with a urinary excretion value of
180 ng/24 h. When applied to our results, the risk of de-
veloping additional cancer due to occupational exposure
to CP is shown in Table 3. Our results indicated that the
risk of developing additional cancer could be reduced by
the combined use of the BSC and CSTD.
Our results also indicated that the PhaSeal system and
cleaning the environment reduced the exposure ofpational exposure to CP
Second test (after PhaSealW)
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setting of a Japanese hospital. Therefore, the continuous
monitoring of personnel and the environment contamin-
ation is necessary to evaluate newly-installed procedures
and the long-term effects of its procedures.
Conclusion
In combination with cleaning according to the Japanese
guidelines, PhaSeal further reduces surface contamin-
ation and healthcare provider exposure of CP could be
achieved at almost undetectable levels.
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